New partnership to accelerate precision medicine research
New partnership to accelerate precision medicine research

Case

New partnership to accelerate precision medicine research

Case

New partnership to accelerate precision medicine research

Odense-based Evosep offers scientists and industry partners integrated tools to unlock precision medicine, accelerated by a new strategic partnership with the American giant Thermo Fisher Scientific. 

When

Evosep, a Denmark-based provider of sample preparation solutions for mass spectrometry-based proteomics, has entered a strategic alliance with Thermo Fisher Scientific, a world leader in serving science. This collaboration marks a significant milestone in advancing robust high-throughput workflows for clinical proteomics by combining Evosep's cutting-edge sample separation technology with Thermo Fisher Scientific's state-of-the-art mass spectrometry instruments and global scale.

A strategic alliance aimed at growth

Rosy Lee, Vice President and General Manager, Life Science Mass Spectrometry, Thermo Fisher Scientific, stated in a press release celebrating the partnership:

"Thermo Fisher is committed to advancing scientific research and enabling breakthroughs in healthcare. This collaboration with Evosep will enable us to provide researchers with cutting-edge tools and technologies. Together, we can help researchers unlock the full potential of mass spectrometry in clinical proteomics." 

The alliance will boost Evosep’s growth and development of new innovative clinical proteomics, representing a major opportunity for the development of new therapies. The company anticipates adding multiple new positions in the near future as its market expands, both geographically but also as the shift to precision medicine drives demand for its technology. To accommodate its growth, Evosep will relocate to new and larger facilities in Odense, Denmark, an emerging hub in the field of proteomics. 

We are thrilled to embark on this collaborative journey with Thermo Fisher Scientific in the paradigm shift from research based applications to drug discovery and precision medicine. This strategic alliance represents a pivotal moment in advancing mass spectrometry-based clinical

proteomics for transformative impacts on healthcare,

Morten Bern

CEO at Evosep 

The strategic alliance between Thermo Fisher Scientific and Evosep is set to significantly influence the pharmaceutical industry by enhancing precision medicine research and facilitating the development of personalized therapies. This collaboration merges Evosep's innovative sample preparation solutions with Thermo Fisher Scientific's advanced mass spectrometry instruments, aiming to improve clinical proteomics workflows. Such advancements could lead to more efficient drug discovery and development processes, potentially reducing the time and cost to bring new therapies to market.

Positioned in Denmark's dynamic biotech ecosystem, the alliance benefits from a rich talent pool and innovative environment. This collaboration not only promises to accelerate growth and innovation within the sector but also strengthens Denmark's role as a global hub for biotechnology and pharmaceutical research.

A Thriving Ecosystem

Denmark has emerged as a hub for commercialising and scaling new innovations in biotechnology. Given their origins in the research ecosystem of Denmark, Evosep draws on a unique pipeline of talent and opportunities to collaborate with some of the many biotech companies in the country. Denmark’s biotech ecosystem is characterized by a dynamic interplay of research institutions, start-ups, and established companies, all driving innovation in the field.

According to the Association of the Pharmaceutical Association (LIF), the pharmaceutical industry accounts for more than 17 percent of total exports from Denmark, with ambitions for increasing this number over the coming decade. The Life Science sector continues to attract investment activity to Denmark, from larger corporate stakeholders to a range of niche companies in the industry.

 

Accelerate your growth in Europe through Denmark

Denmark is consistently ranked as one of the most innovative regions in Europe, with the Life Sciences sector generating opportunities for investors, start-ups, and larger corporate entities with a platform for growth. Being Scandinavia's most cost-efficient location with favourable business conditions, it is not surprising that many companies choose Denmark for their base in Europe or find highly innovative partners, such as Evosep, that have novel technologies ready to be scaled to a global market. 

“From a cost-quality perspective, Denmark is extremely competitive.  We have a highly educated workforce with collaborative academic institutions, ensuring that skills are up to date and knowledge is applied to industry as it emerges. This allows to move quickly from idea to commercial opportunity.  As a digital frontrunner, Danish companies adopt digital and automation solutions quickly, meaning that companies can scale as new technologies are made available. With this partnership, Thermo Fisher and Evosep bring Danish solutions to a whole new set of partners,” 

Vanessa Vega Saenz

Director at Invest in Denmark of the Ministry of Foreign Affairs.

About

Thermo Fisher Scientific

Thermo Fisher Scientific offers a range of products and services including lab equipment, chemicals, and cell culture media, as well as services such as lab informatics, training, and financial and leasing services. It was founded in 1956 and is based in Waltham, Massachusetts.

Read more here: www.thermofisher.com

 

About

Evosep

Evosep is an Odense-based company. Evosep aims to improve quality of life and patient care by radically innovating how protein based clinical diagnostics are performed, initially through collaborations with world-leading scientists about developing new technologies and solutions to make sample separation 10 times faster and 100 times more robust than today’s alternatives. The company was founded in 2016. Evosep is part of a new wave of Odense-based spinouts and start-ups that continue to attract significant growth financing from local investors and, increasingly, from international investors looking to scale Danish solutions for global markets. A recent study by Invest in Odense found that more than €2 billion have been invested into the Life Science sector between 2020 and 2023, with over 3,000 jobs created across more than 40 companies operating in the industry.

Read more here: www.evosep.com

Invest in Denmark

Invest in Denmark is your free and confidential gateway to setting up a business in Denmark – from entry to further expansion.

You can find us in central hotspots in Europe, North America and Asia as part of the Ministry of Foreign Affairs of Denmark. Here, you will meet advisors with corporate backgrounds, industry insights and well-connected networks ready to advise you on every aspect of locating in Denmark.

Get in touch

Want to know how you can become part of the Danish life science ecosystem?

Contact our advisors here:

Copenhagen

  • Sarina Lohmann

    Title: Special Advisor – Maritime and transport – Analysis & Partnerships

    Area: Copenhagen

    Phone: +4533920423

Berlin

Kolding

Silkeborg

Aarhus

Aalborg

Oslo

London

Paris

Munich

New-York

Toronto

Silicon-Valley

Tokyo

Bangalore

Taipei

Shanghai

Singapore